

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
6 November 2003 (06.11.2003)

PCT

(10) International Publication Number  
**WO 03/091736 A2**

(51) International Patent Classification<sup>7</sup>: **G01N 33/92**,  
33/574, B01L 3/00, G01N 33/48

(21) International Application Number: PCT/US03/12674

(22) International Filing Date: 23 April 2003 (23.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/374,629 23 April 2002 (23.04.2002) US

(71) Applicant (*for all designated States except US*): **HOME ACCESS HEALTH CORPORATION** [US/US]; 2401 West Hassell Road, Suite 1510, Hoffman Estates, IL 60195 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **WANDELL, Michael** [US/US]; 7236 Holly Hall Drive, Mercer Island, WA 98040 (US). **VINOGRADOV, Ilia** [RU/US]; 170 Hawthorne, Elmhurst, IL 60126 (US).

(74) Agents: **HOOVER, Allen, E.** et al.; Leydig, Voit & Mayer, Ltd., Two Prudential Plaza, Suite 4900, 180 North Stetson, Chicago, IL 60601-6780 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— *without international search report and to be republished upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



**WO 03/091736 A2**

(54) Title: QUANTITATIVE ANALYSIS OF A BIOLOGICAL SAMPLE OF UNKNOWN QUANTITY

(57) Abstract: Disclosed is a method for testing a modified specimen such as a dried blood spot, plasma or serum specimen, for an analyte of interest, such as cholesterol. In accordance with the disclosed subject matter, the level of the analyte of interest in the medium from which the modified specimen was obtained (e.g., from a patient's blood) is determined based on the level of an analyte in a solution formed from the modified specimen and on the level of at least one normalizing analyte. The analyte and normalizing analyte each may be an ion, compound, biochemical entity, or property of the specimen. Also disclosed are a fluid collector and a fluid collection device.

## QUANTITATIVE ANALYSIS OF A BIOLOGICAL SAMPLE OF UNKNOWN QUANTITY

### RELATED APPLICATION

This application claims priority to prior application serial no. 60/374,629 filed April 23, 2002. The prior application is hereby incorporated by reference in its entirety.

### TECHNICAL FIELD OF THE INVENTION

**[0001]** The invention is in the field of testing, in particular quantitative testing, and in preferred embodiments medical testing. In highly preferred embodiments, the invention is directed towards the testing of body fluid specimens, in particular blood or serum specimens.

### BACKGROUND OF THE INVENTION

**[0002]** Modern medical and wellness practices increasingly make use of self-administered tests and self-collection of test specimens. For instance, U.S. Patents 5,978,466; 6,014,438; 6,016,345; and 6,226,378, issued to Richard Quattrocchi and assigned to Home Access Health Corporation of Hoffman Estates, Illinois, all disclose a method of anonymously testing for a human malady. In accordance with certain embodiments of the subject matter disclosed in the foregoing patents, a patient obtains a blood specimen, typically by pricking his or her finger, and allows the blood to wick onto a blood spot card. After the card has dried, the user then sends the blood spot card to a medical testing facility, where it is tested to determine whether the patient is afflicted with a specific malady. The user may contact the facility anonymously to receive the test result.

**[0003]** The subject matter of the foregoing patents is usable in connection with testing for the presence of human antibodies directed against viral antigens in the blood, for instance, in determining whether a patient is infected with HIV (human immuno-deficiency virus) or with a hepatitis virus. Another document, U.S. Patent 5,435,970, issued to Mamenta et al. and assigned to Environmental Diagnostics, Inc. of Burlington, North Carolina, discloses a device for separating blood cells from biological fluids, for instance, for separating serum from whole blood. The device disclosed in the '970 patent purports to enable the shipment and testing of a serum sample.

**[0004]** The blood spot and serum specimen cards known in the art are suitable for use in the collection of specimens for qualitative testing, i.e., testing for the presence or absence of a given compound in blood or a given medical condition. Heretofore, however, such

blood spot and serum cards have been somewhat unsatisfactory in the quantitative testing of blood and serum specimens.

**[0005]** For instance, general wellness protocol indicates the measurements of a patient's total cholesterol value, which is the number of milligrams of total cholesterol in a deciliter of blood. The value is often used in conjunction with a full lipid profile, which provides levels of triglycerides, HDL (high density lipoprotein) cholesterol, and LDL (low density lipoprotein) cholesterol in a patient's blood. It can be very difficult to gauge the amount of blood or serum that is present in the blood or serum spot card. Particularly when the blood or serum spot card has been self-prepared by a person without medical training, it is difficult to know to certainty whether the spot card has been "underfilled" with less than the intended quantity of blood or serum or "overfilled" with more than the intended quantity. If the amount of blood and serum varies by even a small amount over or under the expected level, the usefulness of the quantitative test can be severely diminished. For instance, it is generally thought that a person's total cholesterol number should be under 200 mg/dl, with cholesterol numbers above 240 mg/dl being considered high and with intermediate cholesterol number being deemed borderline. A 10% margin of error in a cholesterol determination of 220 mg/dl provides no information as to whether the person's cholesterol level is low, intermediate, or high.

**[0006]** In recognition of these problems, the prior art has provided attempts to provide a quantitative determination of analyte levels in a blood specimen. For instance, U.S. Patent 6,040,135, issued to Steven Tyrell and assigned to Biosafe Laboratories, Inc., Chicago, Illinois, purports to disclose a method for correcting for blood volume in a serum analyte determination. The method that is purportedly disclosed by this document is limited and is believed generally to be somewhat unsatisfactory.

**[0007]** The invention seeks to improve upon prior art testing methods, and to provide a method for quantitative testing of modified specimens such as dried blood spot and dried serum specimens.

## THE INVENTION

**[0008]** The invention provides multiple embodiments in the field of testing, in particular medical testing. In accordance with the invention, a modified specimen, preferably a dried blood fluid sample, such as a dried serum or dried whole blood specimen of unknown quantity, is eluted (re-solubilized) and then tested for an analyte. The level of analyte in the blood from which the modified blood specimen was obtained is determined from the

level of analyte in a solution formed from the blood specimen. A normalizing analyte, which in the preferred embodiment is sodium ion, chloride ion, and/or osmolality, is measured and is used in conjunction with the solution level of analyte to determine the level of analyte in the blood from which the modified specimen was obtained. The invention is not limited to the field of medical testing but, to the contrary, is useful in connection with other forms of testing. The invention further provides methods for preparing a database of test results, for preparing a regression using a database of test results, and for providing test results to a user.

**[0009]** In alternative embodiments the invention further encompasses a fluid collector that includes an absorbent substrate coated with a saccharide. A device that includes the collector (as described hereinbelow) also is encompassed by these embodiments.

**[0010]** Other features of preferred embodiments of the invention are set forth hereinbelow.

#### BRIEF DESCRIPTION OF THE FIGURES

**[0011]** FIG. 1 is a flowchart representing steps in a method for calculating the level of an analyte in blood from which a blood specimen was obtained.

**[0012]** FIG. 2 is a flowchart representing steps in an alternative method for calculating the level of an analyte in blood from which a blood specimen was obtained.

**[0013]** FIG. 3 is a flowchart representing steps in a method for providing test result information to a user.

**[0014]** FIG. 4 is a representation of a database record correlating test result information with a test number.

**[0015]** FIG. 5 is a flowchart representing steps in a method for preparing a database of test results and test numbers.

**[0016]** FIG. 6 is a flowchart representing steps in a method for preparing a database of blood analyte levels, solution analyte levels, and solution normalizing analyte levels.

[0017] FIG. 7 is a representation of a database record for a database containing blood analyte level information, solution analyte level information and solution normalizing analyte level information.

[0018] FIG. 8 is a schematic illustration showing various communications between a customer, a results providing facility, and others in connection with a testing protocol.

[0019] FIG. 9 is a perspective view of the obverse side of a blood collection device useful in conjunction with the invention.

[0020] FIG. 10 is a perspective view of the reverse side of the device shown in Fig 9.

#### DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0021] The invention is applicable to the testing of any specimen that is modified from its original form prior to testing. Most commonly, the specimen is a dried specimen, which has been dried to facilitate storage or transport of the specimen or for other purposes. In preferred embodiments of the invention, the specimen is a medical specimen, and in highly preferred embodiments of the invention, the specimen is a blood fluid specimen, by which is contemplated a dried blood spot, a dried serum spot (for instance, as obtained from the device disclosed in U.S. Patent 5,435,970 or that shown in U.S. Patent 4,839,296 issued to Kennedy et al. and assigned to Chem-Elec, Inc. of North Webster, IN), or another blood fluid specimen. The invention is applicable to the testing of the modified specimen for any suitable purpose, and in particular to testing for any analyte in the specimen. For instance, when the specimen is a blood fluid specimen, the test may be a test for prostate specific antigen (PSA), alanineamino transferase (ALT), lipids, such as triglycerides, high density lipoprotein (HDL), low density lipoprotein (LDL), or any other analyte of interest. The invention is applicable to the determination of the level of analyte in the original specimen, for instance, the level of total cholesterol in the blood from which a blood fluid specimen has been obtained. The "level" of the analyte can be expressed in any suitable units, such as molar concentration, weight concentration, or the like. Blood serum is particularly preferred, but it is contemplated that other fractions such as cells, platelets, gamma globulins, plasma or the like may be employed. More generally, any body fluid is susceptible to analysis in conjunction with the invention. In light of the foregoing, the preferred embodiments of the invention will be further described with respect to the determination of the lipid profile in a blood sample, but it should be understood that the invention is not limited thereto.

**[0022]** The facility or other entity that performs the test of the blood fluid specimen may or may not be the same entity that calculates the level of the analyte in the blood fluid specimen or the entity that receives an inquiry from a user and reports the test results to the user. To test the blood fluid specimen, the specimen is first received by the testing entity and is eluted with a liquid, preferably deionized water. It is contemplated that the liquid may be a non-aqueous liquid or may be an aqueous solution, preferably a solution that is free or essentially free of sodium ions or any other normalizing analyte. Alternatively, the solution may have a known amount of the normalizing analyte that can be taken into account during normalization. Preferably, when the testing entity is a testing facility that is intended to test numerous specimens, the eluant is added in a standard amount, which typically is 600  $\mu\text{l}$  (0.6 ml). The eluant in some embodiments may be a buffered electrolyte solution.

**[0023]** After eluting the specimen, preferably the specimen first is tested for the content of a normalizing analyte, such as sodium and chloride content, and in some embodiments osmolality, which generally represents total content of sodium, glucose, and blood urea nitrogen (BUN). To test for sodium and chloride, an ion specific electrode (ISE), such as that sold by Orion may be employed. Preferably, information concerning both the sodium and the chloride content of the solution are obtained, the information being, for instance, analog information such as an electrical signal or digital information such as a printout representing the sodium or chloride content or a digital signal containing information concerning the sodium or chloride content. Most preferably, osmolality also is measured. It should be noted that the invention is not limited to the use of sodium or chloride as normalizing analytes, but to the contrary, any other analyte (which includes a property such as osmolality) may be measured. It is contemplated in preferred embodiments that the sodium, chloride, and osmolality levels are measured against a predetermined range to determine whether the amount of serum is sufficient to perform an adequate test. For instance, it is contemplated that for a cholesterol test, there ideally should be a least approximately 15-17  $\mu\text{l}$  of serum available for testing. If the sodium content of the eluted solution demonstrates that the serum level is far outside this range, the specimen may be rejected as unsuitable for testing. Generally, the specimen may be rejected if there is insufficient serum in the solution, although it is contemplated that in some cases excess serum may be grounds for rejection. Persons skilled in the art may determine how far outside of the desired range the content of normalizing analyte may be allowed to vary without triggering rejection of the specimen.

[0024] Before or after the levels of the normalizing analytes are determined (but preferably after), the solution can be split into four aliquots, or "channels." Each channel is then respectively tested for triglyceride level, HDL level, LDL level, and in a preferred embodiment, ALT level (which may be of interest in informing a physician whether the patient has an abnormal liver which would contraindicate the use of certain drugs). The analyte levels are measured using any technique known in the art or otherwise found to be suitable. For instance, a cholesterol test is disclosed in Allain, C.C., Poon, L.S., Chan, G.S.G., Richmond, W., and Fu, P.C., Clin. Chem. 20:474-75 (1974); see also Roeschlau, P. Brent, E. and Gruber, W.A., Clin. Chem. Clin. Biochem. 12:226 (1974). A test for HDL is disclosed in RiFai, N., Warnick, G.R., Ed., Laboratory Measurement of Lipids, Lipoproteins, and Apolipoproteins (1994). A test for triglycerides is disclosed in McGowan, M.W., Artiss, J.D., Strandbergh, D.R., Zak, B. Clin. Chem. 29:583 (1983). A test for the liver enzyme ALT is disclosed in Wroblewski, F., LaDue, J.S., Proc. Sec. Exp. Biol. Med. 34:381 (1956). The invention is not limited to the foregoing tests or analytes, but to the contrary is applicable to other tests for these or other analytes.

[0025] After the analyte levels have been measured, the level of at least one analyte (and preferably all analytes) in the blood from which the blood fluid specimen was obtained is calculated or otherwise determined based on the solution level of the analyte and on the solution level of at least one normalizing analyte. It is contemplated that the calculation of a blood analyte level may be as simple as multiplying the solution analyte level by the ratio of the blood normalizing analyte level to the solution normalizing analyte level, the blood normalizing analyte level being estimated based on the mean of a normal population distribution. For instance, it is believed that the normal blood sodium level in humans ranges from 136 to 142 mEq/L with a mean of 139 mEq/L and the normal chloride level ranges from 95 to 103 mEq/L with a mean of 99 mEq/L. It is contemplated that through the use of two normalizing analytes, the blood analyte level may be determined by calculating the blood analyte level based on the first normalizing analyte level, calculating the blood analyte level based on the second normalizing analyte level, and then calculating the mean average of the blood analyte levels thus determined.

[0026] If additional normalizing analytes are evaluated, the mean average of all blood level analytes thus determined may be calculated; if desired, where there are at least two normalizing analytes, the average may be weighted towards a specific normalizing analyte. For instance, it is contemplated that Bayesian statistical methods may be used to assign a relative weight to the blood analyte levels determined with reference to each analyte. Such statistical techniques may take into account not only the absolute magnitude of the level of

the normalizing analyte level but also the difference between the actual level and the magnitude expected based on the expected amount of serum, and the standard deviation of the normal population distribution of the analyte. These techniques, sometimes referred to as "maximum likelihood" or "prior probability analysis" techniques, may be used to provide an approximation of the blood analyte level. Further testing concerning such statistical techniques may be found in Casella, G., Berger, R.L., Statistical Inference (1990) and Carlin, B.P., Louis, T.A., Bayes and Empirical Bayes Methods for Data Analysis (2d Ed. 2000).

[0027] Further details concerning the distribution of sodium, chloride, and osmolality in the normal human population may be found in Ravel, Clinical Laboratory Medicine (6th Ed. 1995); see also Penney, M.D. and Walters, G., Ann. Clin. Biochem. 24:566-71 (1987) and Fraser, C.G., Cummings, S.T. Wilkinsen, S.O. et al., Clin Chem. 35: 783-86 (1985). It is further contemplated that a more complicated function of solution analyte level and the levels of one or more normalizing analytes may be employed to calculate the blood analyte levels.

[0028] With reference now to FIG. 1, the generalized method shown therein is applicable where the same entity performs the test and calculates the blood analyte level. Thus in steps 101 and 102 respectively the ISE (e.g., sodium) is immersed into the solution, and sodium level information is obtained. The steps are repeated for the receipt of chloride information, as shown in steps 103 and 104. Information concerning the analyte of interest is received in step 105, and the blood analyte level is calculated in step 106. If, in step 107, it is desired to test an additional analyte for the same specimen, control passes to step 105 where the solution analyte information is received for the new analyte. It is contemplated that the steps of testing for the analytes of interest and the normalizing analytes may be performed by one entity and that the calculation of the blood analyte level may be performed by a separate entity. Thus, for instance, in FIG. 1, steps 101 and 103 may be omitted if the entity calculating the blood analyte level is not the same entity as the entity that performs the test. The method outlined in FIG. 1 is very general, and other steps may be added, steps may be omitted or performed in a different order, and more generally the method may be otherwise performed. For instance, steps of elution and verifying proper serum level are not shown, but are preferably employed.

[0029] It is contemplated that the analyte level, first normalizing analyte level, and second normalizing analyte level may be independently determined and these values used to calculate the blood level of the analyte. For instance, the cholesterol tests hereinbefore



discussed typically are performed via enzymatic techniques in which the optical density of a solution is measured. The "cholesterol value" of the solution then may be expressed as:

$$CV_s = f(OD)$$

wherein  $CV_s$ , the solution cholesterol concentration, is calculated as a function of the optical density, OD, when analytical reagents are added to the sample in accordance with testing techniques known or otherwise found to be suitable. The solution sodium concentration, or  $Na_s$ , may be used to calculate the blood cholesterol level,  $CV_b$ , in the following manner:

$$CV_b = f(CV_s, Na_s)$$

Numerous other forms of such calculations are possible. For instance, a correction factor (CF) may be determined as a function of the solution's sodium level, wherein:

$$CV_b = f(CV_s, CF)$$

and

$$CF = f(Na_s)$$

**[0030]** It is alternatively contemplated that a single apparatus or system may be designed for the calculation of blood analyte levels, wherein an analog or digital electrical signal is generated corresponding to the levels of analyte and normalizing analyte in the solution. For instance, the blood cholesterol number may be calculated as a function of the magnitude of two electrical signals:

$$CV_b = f(E_1, E_2)$$

wherein  $E_1$  represents the magnitude of an electrical signal received from a spectrophotometer in measuring optical density for purposes of evaluating total solution cholesterol level and  $E_2$  represents the magnitude of an electrical signal received from an electrode specific to sodium.

**[0031]** In actual practice, it is contemplated that numerous variables will affect the results obtained for a given set of specimens. For instance, the readings obtained from an ISE may “wander” from day to day, and the device used to collect the blood or other fluid specimen may contain impurities (such as sodium) that have the potential to introduce errors into the test. For this reason, from time to time a “tare” procedure may be employed. Periodically, a plurality of specimens having a known or measurable analyte level is provided, and from these specimens are prepared modified specimens, the modified specimens being specimens as modified in the manner expected of the unknown specimens. For instance, some number (e.g., six) blood specimens may be periodically placed onto a blood spot collection device similar to those used in the field and dried, followed by elution of the dried samples to form solutions. The solutions are then tested for the level of the analyte and one or more normalizing analytes. From these tests, an algorithm for determining the original fluid analyte level as a function of the measured analyte level and the levels of the normalizing analyte or analytes may be derived. Using this algorithm, modified fluid specimens may be analyzed, wherein the levels of analyte and normalizing analyte may be measured, and the level of analyte in the original specimen may be determined as a function thereof. Errors introduced by impurities (such as sodium) in the collection device will be resolved by this methodology, and errors introduced by factors such as machine calibration will be resolvable with periodic re-calculation of the algorithm. The tare procedure may be performed occasionally or regularly at predetermined intervals (e.g., every day, week, month, or year).

**[0032]** The foregoing exemplary equations are not meant to be exhaustive but, to the contrary, are intended to illustrate that innumerable variants of the methods for calculating the blood analyte level are included within the scope of the invention. For instance, with respect to FIG. 2, in one such variant, an ISE (sodium) is immersed into an eluted sample at step 201, and a signal corresponding to the sodium level is received at step 202. The signal may be a digital signal, or may be an analog signal, the level of which is recorded. At steps 203 and 204, the same steps are repeated for chloride level, and at steps 205 and 206 respectively, a test for the analyte is performed and a signal is received corresponding to the analyte level. At step 207, the solution sodium level is calculated; at step 208, the chloride level is calculated, and at step 209, the solution analyte level is calculated. At step 210, the blood analyte level is calculated, in this instance based on the magnitude of the solution sodium level, the solution chloride level, and the solution analyte level. If, at step 211, it is desired to test for an additional analyte for the same specimen, control passes to step 205. In such case, if the solution sodium and chloride level have been stored, steps 207 and 208 may be omitted after a signal is received corresponding to the second analyte

level. The process may be controlled by any suitable microprocessor or microcontroller (not shown).

**[0033]** As stated hereinabove, it is contemplated that the entity who provides test results to a user, who may or may not be the health care professional who has ordered the test, in turn may be the same or different entity from the entity which performs the calculation of the blood analyte level, which in turn may be the same or different entity from the entity which tests the specimen and generates information corresponding to the analyte level or levels and the normalizing analyte level or levels. A very general protocol for a results providing facility is set forth in FIG. 3, wherein an inquiry is received from a user at step 301, and the user is prompted for his or her test number at step 302. At step 303, the test number is received, and at step 304, a test result database is queried for test result information. The information is received at step 305 and is provided to the user at step 306.

**[0034]** With further reference to FIG. 4, the test result database described above may be structured in any suitable manner. With respect to, for instance, database record 400, the test result information 401, which in the illustrated embodiment includes two items of information, blood analyte information 1 and blood analyte information 2, is correlated with the test number 402. The test number may be an anonymous test number or may be a test number that is associated with a user, for instance, elsewhere in the database record 400 (not shown) or in a different database.

**[0035]** With reference to FIG. 5, the database may be prepared by creating a database record (shown in step 501), receiving test result information and a test number (shown in steps 502 and 503 respectively) and, as shown in step 504, entering the test number and test result information into the database record. More information concerning the role of a results providing facility in a medical or wellness testing protocol can be found in the aforementioned Quattrocchi patents and in copending application Serial No. 09/709,884.

**[0036]** The invention additionally contemplates a method for preparing a database for use in calculating blood analyte levels. The blood analyte level may be calculated with specific reference to the database, or alternatively the database may be used in conjunction with the preparation of an algorithm for enabling blood level calculation. The database preferably is prepared with reference to blood having a known level of cholesterol or other analyte of interest. Plural specimens of blood having different levels of the analyte are then reduced to an modified specimen, such as a blood spot or serum specimen, and each

specimen is analyzed for the analyte of interest and for a normalizing analyte. For instance, with respect to FIG. 6, a database record is created at step 601, and known blood analyte level information is received at step 602. Information as to the solution analyte level and the level of two normalizing analytes, sodium and chloride, for example, are received at steps 603-605, and at step 606, the information received is entered into the database record. If, at step 607, an additional database record is to be created, control passes to step 601, wherein a new database record is created for the new specimen. It should be noted that the order of the steps is not critical, and indeed the database may be prepared sequentially with respect to each blood specimen (i.e., each specimen is reduced to an modified specimen, tested, and the results entered into a database record prior to altering the next specimen of blood), sequentially with respect to database record (wherein all of the blood specimens are reduced to modified specimens prior to entering the first database records) or by any other suitable methodology. A database record 700 as shown in FIG. 7 is thus prepared, with entries 701 through 704 representing respectively blood analyte level, solution analyte, solution sodium level, and solution chloride level.

**[0037]** As discussed above, rather than being calculated, the blood analyte level in a blood fluid specimen may be determined with reference to the database, for instance, by finding the solution analyte level and solution normalizing analyte level or levels in the database that are closest to those of the specimen. Alternatively, any suitable statistical or mathematical technique may be used to derive an algorithm for calculating the blood analyte level from the solution analyte level and at least one normalizing analyte level. In some embodiments, the algorithm is first order with respect at least to the solution analyte level, and may be first order with respect to the solution analyte level and one or both normalizing analyte levels.

**[0038]** The invention preferably is conducted in accordance with the general schematic set forth in FIG. 8. Generally the customer 801 purchases a test kit from a physician or retail store 802 (transfer of the kit is shown via transfer communication 805). The test kit (not shown) preferably includes instrumentalities for allowing the customer to obtain a blood, serum or serum spot specimen. For instance, as discussed more fully in the aforementioned Quattrocchi patents, the test kit may include a lancet for pricking the user's finger, a blood spot card, or serum spot card, (or the device shown in Figs. 9 and 10 hereinafter discussed) an informed consent form, and a test number. After preparing the blood, serum or serum spot card, the customer sends the dried blood specimen to a results providing facility 803 as shown via transfer communication 806. In the illustrated embodiment, the results providing facility 803 sends the specimen to a separate testing

facility 804, as shown via transfer communication 809. As shown via communication 810, the testing facility provides the test results to the results providing facility. The results may be "raw" results, i.e., results in which the level of the analyte in the blood has not been determined or obtained, or alternatively the testing facility may calculate the blood analyte level and report that result to the results providing facility. As shown at communication 807, the customer contacts the results providing facility, and at communication 808, the results providing facility provides the test results to the customer. Optionally, the results providing facility may be equipped to communicate directly with the physician's office, as shown at communications 811 and 812. Except where transfer of a physical specimen is required, the communication may be made via any means or method now known or hereinafter discovered, for instance, via telephone, wireless communication, electronic mail or "chat" or other electronic communication, or other form of communication.

**[0039]** With reference now to Figs. 9 and 10, the illustrated fluid collection device 900 includes two gangs 901, 901, each comprising a fluid collector 903, 904 that is disposed between a superstrate sheet 905 and a substrate sheet 906 and that is generally fixed with respect to the superstrate sheet 905. The fluid collector is ordinarily connected to the substrate sheet 906 (a portion of which is visible) at one end 907, 908, although the collector may be flexible and thus not entirely fixed with respect to the substrate sheet 905. The substrate is provided with at least one aperture (two shown as 909, 910) by which a user may fluidically transfer blood to the collector. In the illustrated embodiments, secondary apertures 911, 912 are provided. To use the device, a user dispenses blood onto the collector, whereby some or all of the blood wicks in the direction shown by arrow 913 until the portions 914, 915 of the collectors 903, 904 visible through the secondary apertures 914, 915 become tainted, whereupon the user is provided with an indication that sufficient blood has been collected. In the illustrated embodiments, instructions 917 are provided on the substrate sheet 905 and identification information spaces 918 (shown in Fig. 10) are provided on the substrate sheet 906. The device may be provided with non-textual machine-readable indicia (such as barcode 919).

**[0040]** In a highly preferred embodiment of the invention, the fluid collector is an absorbent paper or glass fiber substrate that is coated with a saccharide, preferable a mono- or di-saccharide and most preferably xylose. The substrate should be one that permits at least substantial separation of the red blood cell component of blood cells from other portions of the blood (i.e., serum). It is believed that the saccharide component permits more effective recovery of the serum components from the substrate sheet. The substrate may be coated only at the surface on one or both sides with the saccharide, but preferably

the substrate is coated on internal surfaces as well as on the exterior surface. In one embodiment, 180  $\mu$ l of a 5% solution of xylose is applied to the internal surface of the 0.8 x 7 cm substrate (such that substantially all of the substrate is wetted) and allowed to air dry. If the fluid collector is used in the device shown in Figs. 9 and 10, the blood cells will remain near the end of the collection device (opposite the direction of arrow 913) while the serum will wick toward the other end of the card. Upon receipt by a testing laboratory, a portion of the fluid collector may be excised and eluted. Preferably, the excised portion includes a portion of the collector "above" the terminal wicking point of the serum. One commercial product (Whatman GF/AVA paper) contains sodium, and it is believed that by excising filter paper above the terminal wicking point a consistent amount of sodium will be introduced into the eluted fluid. The device may be prepared by applying a solution of the saccharide to the substrate

**[0041]** The invention enables venous blood analyte levels to be determined from capillary blood specimens. It is contemplated that in most embodiments the solution analyte level will be normalized to the venous blood level of the analyte, but it is also contemplated that the solution value may be normalized to capillary blood level (or for that matter a different blood level).

**[0042]** The databases discussed herein may be created and stored as computer files on a computer readable medium, such as a diskette, hard disk, CD-ROM, DVD-ROM, ROM chip or EPROM chip, or any other suitable medium as may be now known or hereinafter discovered. The tests for the analyte and normalizing analytes may be performed by any conventional or otherwise suitable technique now or hereinafter found to be suitable, and likewise the analyte and normalizing analyte (which may be discrete atoms, ions, compounds, biochemical materials, or properties) may be those specifically described herein or others as may be found suitable for use in conjunction with the invention.

**[0043]** The following examples are provided to illustrate the invention, but should not be construed as limiting the invention in scope unless otherwise indicated. Unless otherwise indicated in these examples, the measured analyte level was corrected using sodium as the sole normalizing analyte. The correction was made using a simple linear regression. It should be understood that more complex single variable and multivariate regressions may be used in conjunction with the invention, and thus the statistical techniques employed in these examples should be viewed as non-limiting.

## EXAMPLE 1

**[0044]** This example demonstrates the performance of the invention in the measurement of total cholesterol.

**[0045]** Fifteen patients were used to obtain blood specimens (micro-serum specimens) via venal puncture. Serum from each specimen was spotted and dried on filter paper with applied volumes ranging from approximately 8 to 16  $\mu$ l. The number of spots for each blood specimen is listed in the column "No." in the table below. Each spot was eluted and measured for cholesterol and sodium. For each specimen for each patient, the normalized cholesterol level was calculated based on the level of a measured analyte in the fluid (cholesterol) and a normalizing analyte (sodium). The normalized cholesterol level was obtained according to the present invention using linear regression techniques to yield the following function:  $\text{Normalized Cholesterol} = \text{Measured Cholesterol} / ((-0.003306) + 0.9781 \times (\text{Measured Sodium} / 139))$ , where 139 (mEq/L) is the population mean for sodium. The regression was calculated based on five direct measurements of the cholesterol level from the same blood sample, as listed in the column "Mean Serum Cholesterol." The mean average of the normalized cholesterol values for each patient is given in the column "mean normalized cholesterol" and the coefficient of variation of the normalized cholesterol levels obtained for each patient is listed in the column designated "Normalized Cholesterol CV%."

Patient	No.	Mean Serum Cholesterol	Mean Normalized Cholesterol	Normalized Cholesterol CV%
A	11	152.35	153.68	3.85
Ja	12	165.79	162.50	1.42
Il	14	180.93	180.47	4.61
Ca	12	186.20	182.28	0.70
Br	10	187.06	185.35	2.93
Mi	12	187.14	186.21	1.85
Gr	12	187.42	189.14	1.65
Ed	12	200.38	197.18	1.36
Tr	11	220.83	221.89	2.00
Bb	11	232.65	233.06	1.89
Ma	11	236.73	245.53	1.02
Jo	11	237.37	237.24	1.95
JJ	14	262.41	259.24	1.75
Kt	12	264.30	268.23	1.86

Patient	No.	Mean Serum Cholesterol	Mean Normalized Cholesterol	Normalized Cholesterol CV%
TT	13	269.36	273.53	2.79

[0046] A comparative linear regression was generated for the data points collected in this Example. The linear fit followed the following equation:

Mean Normalized Cholesterol =  $-7.97 + 1.04 \times \text{Mean Serum Cholesterol}$ ,  
with the correlation coefficient, expressed as  $R^2$ , being greater than 0.99.

## EXAMPLE 2

[0047] This example demonstrates the performance of the invention in the measurement of HDL.

[0048] The same dried spots from the same fifteen patients in Example 1 were used to obtain a measured value for HDL. The normalized HDL level was obtained according to the present invention using linear regression techniques yielding the following function: Normalized HDL = HDL / (0.0158 + 1.060 x (Sodium / 139)). The following data was measured or calculated in the same manner as in Example 1.

Patient	No.	Mean Serum HDL	Mean Normalized HDL	Normalized HDL CV%
II	14	45.77	47.03	2.35
A	11	46.05	47.77	2.17
Jo	11	47.40	48.50	2.12
Ja	12	48.87	53.22	2.23
JJ	14	49.07	48.15	1.68
Gr	12	49.64	52.45	1.62
Mi	12	59.96	58.95	1.69
Br	10	57.20	55.83	2.66
Ed	12	71.00	71.09	0.92
Kt	12	73.08	72.46	1.53
TT	13	76.16	75.77	2.27
Ca	12	78.01	75.93	1.50
Bb	11	78.77	73.35	1.99
Ma	11	87.84	84.75	0.94



Patient	No.	Mean Serum HDL	Mean Normalized HDL	Normalized HDL CV%
Tr	11	91.15	86.42	1.46

[0049] A comparative linear regression was generated for the data points collected in this Example. The linear fit followed the following equation:

Mean Normalized HDL =  $8.15 + 0.87 \times \text{Mean Serum HDL}$ ,  
with the correlation coefficient, expressed as  $R^2$ , being greater than 0.99.

### EXAMPLE 3

[0050] This example demonstrates the performance of the invention in the measurement of triglycerides (TG).

[0051] The same dried spots from the same fifteen patients in Example 1 were used to obtain a measured value for TG. The normalized TG level was obtained according to the present invention using linear regression techniques yielding the following function:  
Normalized TG = TG / ((-0.0136) + 0.9307 x (Sodium / 139)). The following data was measured or calculated in the same manner as in Example 1.

Patient	No.	Mean Serum TG	Mean Normalized TG	Normalized TG CV%
Ca	12	37.63	38.76	1.95
Bb	11	46.86	48.55	1.75
A	11	48.75	50.16	2.73
Ja	12	49.68	49.94	3.31
Kt	12	52.15	48.19	1.32
Br	10	55.00	56.56	4.14
Ma	11	56.05	56.40	2.03
II	14	59.09	60.88	6.22
Ed	12	62.91	61.65	1.25
Tr	11	66.69	67.66	1.63
TT	13	68.76	72.14	13.37
Mi	12	71.84	72.63	1.62
Jo	11	109.28	107.10	2.27
JJ	14	117.31	112.24	5.03
Gr	12	139.47	136.74	2.13

**[0052]** A comparative linear regression was generated for the data points collected in this Example. The linear fit followed the following equation:

$$\text{Mean Normalized TG} = 3.36 + 0.95 \times \text{Mean Serum TG},$$

with the coefficient, expressed as  $R^2$ , being greater than 0.995.

#### EXAMPLE 4

**[0052]** This example demonstrates the performance of the invention in the measurement of LDL. The same observations from the same fifteen patients in Example 1, 2 and 3 were used to calculate a value for LDL in serum and a value for LDL in MSS according to the Friedewald formula:

$$\text{Mean Serum LDL} = \text{Mean Serum Cholesterol} - \text{Mean Serum HDL} - \text{Mean Serum TG}/5$$

Mean Normalized LDL = Mean Normalized Cholesterol – Mean Normalized HDL – Mean Normalized TG/5, respectively.

The following data was calculated (mean serum LDL was calculated from the mean values reported in Examples 1-3)

Patient	No.	Mean Serum LDL	Mean Normalized LDL	Normalized LDL CV%
A	11	96.55	95.30	5.36
Ca	12	100.66	98.82	1.17
Ja	12	106.98	99.22	2.32
Gr	12	109.88	109.00	2.19
Mi	12	115.81	112.90	2.80
Tr	11	116.35	121.21	3.11
Ed	12	116.80	113.76	1.98
Br	10	118.86	118.21	3.23
Il	14	123.34	119.75	5.72
Ma	11	137.68	149.45	1.72
Bb	11	144.51	150.01	2.12
Jo	11	168.11	167.55	2.66
Tt	13	179.45	183.33	3.33
Kt	12	180.78	186.13	2.19
JJ	14	189.88	189.54	1.89

[0053] A comparative linear regression was generated for the data points collected in this Example. The linear fit followed the following equation:

$\text{Mean Normalized LDL} = -8.16 + 1.07 \times \text{Mean Serum LDL},$   
with the correlation, expressed as  $R^2$ , being equal to 0.98.

#### EXAMPLE 5

[0054] This example demonstrates the performance of the invention in the measurement of total cholesterol.

[0055] One hundred thirty-two patients were used to obtain blood via venal puncture (venous blood specimens) and by pricking their fingers (capillary blood specimens). Capillary blood was spotted on xylose-coated Whatman GF/AVA filter paper, using a device similar to that shown in Fig. 9. Capillary blood specimens were dried and the portion of the filter paper which contained separated serum was cut out and eluted. Eluate from each specimen was measured for cholesterol and sodium. The normalized cholesterol level was obtained according to the present invention using a variable formula:  $\text{Normalized Cholesterol} = \text{Measured Cholesterol} / (A + B \times (\text{Measured Sodium} / 139))$ . In this equation, A and B were scalar values that were periodically recalculated based on the "tare" procedure heretofore described, whereby a regression for six patients was calculated and the A and B values from this regression were used to calculate normalized cholesterol values for specimens analyzed before the next tare period. Actual (directly measured in venous blood) and calculated normalized cholesterol values for these patients are given below.

Patient	Serum Cholesterol	Normalized Cholesterol
1	172.68	157.54
2	149.25	154.61
3	176.81	175.60
4	189.78	187.41
5	170.38	173.03
6	189.67	188.80
7	130.52	128.80
8	266.76	276.31

9	151.29	152.49
10	219.86	211.23
11	242.00	251.07
12	232.41	230.66
13	173.09	176.48
14	190.89	190.86
15	264.47	260.46
16	236.18	244.49
17	272.58	279.76
18	240.29	228.83

19	169.32	166.57
20	192.02	195.03
21	239.83	235.33
22	225.13	225.13
23	169.40	156.05
24	197.93	183.67
25	151.59	146.26
26	235.43	247.88
27	178.84	170.79
28	196.40	191.34
29	240.99	230.52
30	171.53	173.95
31	229.43	229.43
32	217.54	223.84
33	187.23	183.58
34	175.68	173.95
35	174.69	172.34
36	251.23	249.20
37	203.70	185.98
38	123.30	114.96
39	136.04	127.97
40	251.33	243.27
41	216.14	218.02
42	145.14	156.86
43	208.58	203.43
44	250.25	245.07
45	235.76	250.40
46	193.19	187.83
47	211.75	223.38
48	221.15	226.04
49	199.41	196.35
50	249.35	259.44
51	166.46	165.63
52	154.64	151.56
53	187.36	190.37

54	256.78	260.40
55	230.59	222.39
56	208.57	224.14
57	183.92	181.28
58	159.73	156.20
59	155.31	153.59
60	205.29	197.61
61	204.49	198.97
62	219.21	221.45
63	122.83	114.88
64	175.13	176.48
65	201.35	211.70
66	216.66	209.09
67	227.50	231.96
68	151.28	153.23
69	130.10	128.40
70	175.95	173.45
71	182.38	183.21
72	201.03	195.89
73	175.86	189.73
74	146.10	149.88
75	116.17	103.88
76	193.58	197.59
77	291.91	296.11
78	184.93	185.49
79	145.82	141.34
80	182.73	180.78
81	175.84	170.03
82	148.99	151.67
83	212.79	213.40
84	228.82	225.39
85	218.44	229.26
86	169.43	173.84
87	151.43	157.96
88	217.96	218.63

89	239.39	244.17
90	148.62	152.86
91	136.81	132.60
92	179.13	173.31
93	121.10	119.61
94	165.37	163.34
95	117.65	132.34
96	190.25	184.44
97	201.78	206.49
98	133.26	137.69
99	225.84	221.67
100	244.66	230.25
101	164.72	168.10
102	150.75	146.82
103	163.57	170.41
104	196.06	198.89
105	213.32	206.01
106	186.62	183.13
107	163.46	162.71
108	244.58	250.24
109	231.82	231.32
110	171.94	172.27
111	207.12	209.36

112	205.41	209.00
113	157.54	156.02
114	191.41	190.59
115	192.20	197.37
116	193.52	183.72
117	257.83	248.49
118	178.32	171.44
119	203.64	209.32
120	210.36	230.25
121	207.74	220.04
122	200.05	205.38
123	216.34	219.09
124	190.10	179.14
125	293.34	272.48
126	228.57	226.02
127	171.60	174.88
128	142.80	148.94
129	197.16	205.05
130	220.50	218.43
131	220.32	231.50
132	255.78	255.23

**[0056]** A comparative linear regression was generated for the data points collected in this Example. The linear fit followed the following equation:

Normalized Cholesterol =  $-1.16 + 1.00 \times \text{Serum Cholesterol}$ , with the correlation coefficient, expressed as  $R^2$ , being 0.966.

#### EXAMPLE 6

This example demonstrates the performance of the invention in the measurement of HDL. The dried spots and venous blood specimens from the same one hundred thirty-two patients in Example 5 were used to measure HDL in capillary blood and compare it to a

measured value for HDL in venous blood. The normalized HDL level in capillary blood was obtained according to the present invention using a formula:  $\text{Normalized HDL} = \text{Measured HDL} / (A + B \times (\text{Measured Sodium} / 139))$ , where A and B were obtained as previously described. The following results were observed.

Patient	Serum HDL	Normalized HDL
1	58.90	61.12
2	41.28	42.33
3	38.54	39.15
4	48.84	46.19
5	61.56	54.98
6	52.68	48.79
7	47.69	45.15
8	34.69	39.49
9	57.45	56.32
10	38.00	36.33
11	47.53	42.14
12	60.04	58.94
13	36.08	37.35
14	46.09	48.37
15	42.22	42.82
16	34.70	38.98
17	55.76	55.79
18	21.16	24.53
19	55.33	55.69
20	44.66	42.65
21	83.26	81.00
22	44.33	46.14
23	40.71	40.69
24	47.24	43.98
25	49.46	47.71
26	44.37	43.30
27	50.16	48.34
28	55.49	61.30
29	58.90	61.12

30	41.28	42.33
31	38.54	39.15
32	48.84	46.19
33	61.56	54.98
34	52.68	48.79
35	47.69	45.15
36	34.69	39.49
37	57.45	56.32
38	38.00	36.33
39	47.53	42.14
40	60.04	58.94
41	36.08	37.35
42	46.09	48.37
43	42.22	42.82
44	34.70	38.98
45	55.76	55.79
46	21.16	24.53
47	55.33	55.69
48	44.66	42.65
49	83.26	81.00
50	44.33	46.14
51	40.71	40.69
52	47.24	43.98
53	49.46	47.71
54	44.37	43.30
55	50.16	48.34
56	55.49	61.30
57	49.27	45.94
58	51.73	51.78
59	38.07	36.98

60	38.22	38.49
61	43.57	45.05
62	54.16	51.46
63	38.66	34.13
64	50.14	48.65
65	57.94	54.11
66	46.02	44.67
67	49.21	52.36
68	43.15	45.31
69	37.20	38.42
70	49.66	50.00
71	63.00	65.28
72	79.92	79.17
73	37.12	44.57
74	59.14	60.35
75	32.49	28.57
76	56.08	59.37
77	64.22	70.04
78	46.54	48.66
79	37.68	37.28
80	75.41	74.70
81	44.06	44.73
82	40.65	40.88
83	93.40	91.97
84	40.97	47.04
85	69.63	75.17
86	36.13	38.81
87	34.88	36.42
88	43.90	49.40
89	63.29	66.41
90	49.21	49.65
91	29.54	31.27
92	49.30	49.87
93	35.82	34.39
94	49.66	51.20

95	39.01	39.79
96	36.92	34.49
97	43.40	43.45
98	48.70	45.97
99	42.15	41.04
100	59.09	55.11
101	49.46	47.04
102	33.36	29.81
103	49.36	47.93
104	43.02	39.12
105	39.81	41.06
106	60.29	56.62
107	59.84	55.33
108	84.77	82.31
109	55.20	55.72
110	54.77	56.06
111	69.16	67.30
112	38.18	40.50
113	37.11	36.49
114	51.31	49.24
115	39.69	42.54
116	61.17	56.56
117	29.94	30.25
118	75.50	77.62
119	56.94	57.49
120	68.89	71.30
121	37.89	40.82
122	73.57	72.14
123	78.31	78.16
124	48.88	47.45
125	83.96	79.26
126	95.12	92.48
127	51.44	52.50
128	38.88	38.10
129	41.70	44.58

<b>130</b>	<b>47.80</b>	<b>46.24</b>
<b>131</b>	<b>56.42</b>	<b>59.35</b>

<b>132</b>	<b>55.14</b>	<b>56.98</b>
------------	--------------	--------------

**[0057]** A comparative linear regression was generated for the data points collected in this Example. The linear fit followed the following equation:

Normalized HDL =  $2.47 + 0.953 \times \text{Serum HDL}$ ,  
with the correlation coefficient, expressed as  $R^2$ , being greater than 0.96.

#### EXAMPLE 7

**[0058]** This example demonstrates the performance of the invention in the measurement of triglycerides (TG). The dried spots and venous blood specimens from the same one hundred thirty-two patients in Example 5 were used to measure TG in capillary blood and compare it to a measured value for TG in venous blood. The normalized TG level in capillary blood was obtained according to the present invention using the formula: Normalized TG = Measured TG / (A + B x (Measured Sodium / 139)), where A and B were obtained as previously described. The following results were observed.

<b>Patient</b>	<b>Serum TG</b>	<b>Normalized TG</b>
<b>1</b>	<b>73.24</b>	<b>55.65</b>
<b>2</b>	<b>97.89</b>	<b>97.31</b>
<b>3</b>	<b>45.26</b>	<b>38.38</b>
<b>4</b>	<b>70.31</b>	<b>60.30</b>
<b>5</b>	<b>119.71</b>	<b>119.33</b>
<b>6</b>	<b>105.97</b>	<b>100.56</b>
<b>7</b>	<b>77.47</b>	<b>73.30</b>
<b>8</b>	<b>220.18</b>	<b>236.94</b>
<b>9</b>	<b>191.79</b>	<b>203.18</b>
<b>10</b>	<b>177.10</b>	<b>177.03</b>
<b>11</b>	<b>112.19</b>	<b>116.71</b>
<b>12</b>	<b>73.24</b>	<b>55.65</b>
<b>13</b>	<b>97.89</b>	<b>97.31</b>

<b>14</b>	<b>45.26</b>	<b>38.38</b>
<b>15</b>	<b>70.31</b>	<b>60.30</b>
<b>16</b>	<b>119.71</b>	<b>119.33</b>
<b>17</b>	<b>157.70</b>	<b>164.69</b>
<b>18</b>	<b>122.09</b>	<b>124.56</b>
<b>19</b>	<b>66.86</b>	<b>63.24</b>
<b>20</b>	<b>138.31</b>	<b>151.08</b>
<b>21</b>	<b>146.08</b>	<b>137.36</b>
<b>22</b>	<b>95.85</b>	<b>97.05</b>
<b>23</b>	<b>77.27</b>	<b>60.69</b>
<b>24</b>	<b>85.44</b>	<b>82.87</b>
<b>25</b>	<b>86.25</b>	<b>77.32</b>
<b>26</b>	<b>112.51</b>	<b>110.68</b>
<b>27</b>	<b>176.25</b>	<b>184.16</b>
<b>28</b>	<b>190.63</b>	<b>189.57</b>



29	95.17	98.92
30	98.52	98.76
31	102.13	97.07
32	117.77	128.91
33	123.08	125.56
34	135.72	132.69
35	76.46	71.14
36	230.90	210.77
37	80.41	67.66
38	99.43	85.63
39	86.87	91.07
40	125.01	120.98
41	362.90	322.04
42	132.98	118.47
43	83.21	75.43
44	52.45	53.34
45	53.91	50.52
46	349.76	357.87
47	135.25	139.57
48	209.20	208.33
49	374.36	386.86
50	74.90	79.81
51	395.31	399.34
52	56.38	54.87
53	217.08	258.78
54	52.83	71.35
55	136.53	144.81
56	115.98	118.45
57	78.41	62.45
58	70.38	65.13
59	91.00	68.59
60	180.98	179.72
61	163.32	188.88
62	72.16	65.05
63	102.89	101.45

64	50.24	49.05
65	184.45	195.42
66	183.07	194.25
67	65.28	65.04
68	111.40	109.43
69	67.25	87.27
70	74.92	72.25
71	100.19	105.33
72	136.82	132.52
73	119.29	129.90
74	119.76	119.83
75	121.90	125.90
76	75.55	80.65
77	74.44	89.06
78	226.78	243.05
79	71.19	78.23
80	98.89	93.66
81	127.93	135.56
82	333.65	352.31
83	97.18	91.96
84	139.77	133.20
85	73.23	72.05
86	160.00	148.64
87	131.69	133.49
88	69.07	66.79
89	271.22	248.43
90	91.86	98.00
91	231.14	224.76
92	153.65	171.85
93	115.95	107.16
94	263.50	257.68
95	95.38	92.85
96	143.96	125.21
97	110.10	131.36
98	97.72	93.75

99	158.22	151.23
100	123.80	127.26
101	279.56	271.61
102	192.26	176.02
103	59.41	59.23
104	197.04	186.32
105	182.29	170.98
106	96.16	91.53
107	80.46	72.56
108	65.55	68.16
109	215.37	210.92
110	186.09	191.14
111	96.41	96.52
112	78.68	80.54
113	83.96	73.13
114	207.32	208.03
115	37.41	37.32
116	103.17	93.38

117	193.21	210.21
118	119.46	103.27
119	67.57	58.99
120	119.56	117.34
121	75.42	52.90
122	311.18	315.01
123	67.72	68.28
124	127.36	129.28
125	59.82	64.57
126	85.54	83.90
127	43.24	41.49
128	85.09	78.05
129	95.15	99.45
130	92.21	75.05
131	72.46	88.51
132	56.52	57.13

**[0059]** A comparative linear regression was generated for the data points collected in this Example. The linear fit followed the following equation:

$$\text{Normalized TG} = -2.5 + 1.01 \times \text{Serum TG},$$

with the coefficient, expressed as  $R^2$ , being 0.98.

#### EXAMPLE 8

**[0053]** This example demonstrates the performance of the invention in the measurement of LDL. The same observations from the same one hundred thirty-two patients in Example 5, 6 and 7 were used to calculate a value for LDL in serum and a value for LDL in MSS according to the Friedewald formula:

$$\text{Serum LDL} = \text{Serum Cholesterol} - \text{Serum HDL} - \text{Serum TG}/5$$

$$\text{Normalized LDL} = \text{Normalized Cholesterol} - \text{Normalized HDL} - \text{Normalized TG}/5.$$

The following results were calculated:

	Serum	Normalized
Patient	LDL	LDL

1	110.85	101.31
2	97.93	101.60

3	109.82	103.89
4	110.51	112.89
5	108.21	107.74
6	126.07	121.49
7	49.76	54.13
8	173.19	173.53
9	78.72	77.71
10	129.52	119.61
11	174.74	180.58
12	149.04	140.09
13	98.72	101.13
14	115.22	115.25
15	187.28	180.56
16	146.29	158.21
17	195.20	200.00
18	167.30	161.22
19	101.87	99.92
20	122.26	127.45
21	168.27	164.79
22	149.27	148.28
23	100.92	85.06
24	129.40	115.93
25	92.09	88.71
26	165.02	175.92
27	114.88	104.61
28	94.16	90.62
29	154.94	142.87
30	114.95	117.39
31	144.71	148.13
32	152.62	164.12
33	105.78	111.48
34	105.62	106.95
35	101.99	102.99
36	143.96	145.31
37	119.65	105.96

38	68.65	63.55
39	78.02	75.16
40	180.50	174.23
41	110.10	109.10
42	72.00	80.58
43	124.52	118.94
44	140.68	128.72
45	165.02	178.66
46	92.96	83.43
47	145.15	156.72
48	133.07	131.63
49	105.59	101.08
50	177.71	184.34
51	102.56	101.25
52	91.72	95.09
53	123.82	129.64
54	194.21	203.38
55	144.23	138.11
56	120.42	125.06
57	120.22	122.32
58	87.42	84.13
59	107.19	106.80
60	130.18	120.03
61	124.30	115.07
62	151.99	156.98
63	61.89	58.86
64	111.54	110.38
65	128.43	143.14
66	150.60	143.35
67	150.93	153.10
68	84.28	81.94
69	68.95	66.01
70	101.92	98.27
71	104.27	101.79
72	106.22	98.91

73	93.38	96.56
74	72.72	73.88
75	63.90	56.58
76	111.92	111.11
77	160.96	155.60
78	118.95	118.43
79	80.19	77.42
80	92.68	91.67
81	99.78	95.56
82	82.00	84.09
83	105.58	108.07
84	133.61	128.66
85	130.44	134.49
86	87.08	90.07
87	85.82	87.16
88	150.87	147.80
89	123.40	126.22
90	80.33	84.64
91	78.47	76.28
92	107.81	97.16
93	65.74	66.47
94	84.06	81.90
95	53.88	67.10
96	97.42	95.63
97	119.93	127.83
98	72.69	79.87
99	144.28	143.36
100	149.12	140.94
101	96.03	102.76
102	101.29	102.50
103	101.09	108.85

104	109.96	117.58
105	136.29	126.72
106	107.05	107.20
107	87.89	91.28
108	143.01	153.30
109	135.15	134.00
110	109.68	108.74
111	117.33	123.38
112	128.59	126.45
113	96.53	98.88
114	126.58	129.56
115	128.60	131.36
116	117.26	116.58
117	165.65	155.24
118	89.27	80.15
119	121.23	125.97
120	129.51	146.03
121	152.74	162.44
122	117.83	124.94
123	121.01	125.32
124	122.19	111.80
125	190.94	178.21
126	118.95	115.83
127	108.85	110.95
128	76.17	84.41
129	116.38	120.15
130	116.39	113.82
131	134.85	142.75
132	173.09	172.40

[0060] A comparative linear regression was generated for the data points collected in this Example. The linear fit followed the following equation:

$$\text{Normalized LDL} = -0.25 + 1.00 \times \text{Serum LDL},$$

with the correlation, expressed as  $R^2$ , being equal to 0.96.

**[0061]** It is thus seen that the invention provides a method for determining the level of an analyte in a specimen.

**[0062]** While particular embodiments to the invention have been described herein, the invention is not limited thereto, but to the contrary should be deemed defined by the full scope of the appended claims. All references and pending applications cited herein are hereby incorporated by reference in their entireties.

## WHAT IS CLAIMED IS:

1. A method for determining the level of an analyte in blood from a solution formed from a dried blood fluid specimen, said blood fluid specimen being a plasma or serum specimen, comprising:

in either order, measuring the analyte level in said solution and measuring the level of a normalizing analyte; and

determining the analyte level in the blood from which said blood fluid specimen was collected based on said analyte level in said solution and on said level of said normalizing analyte in said solution.

2. The method according to claim 1, said analyte being ALT.

3. The method according to claim 1, said analyte being a cholesterol.

4. The method according to claim 1, said analyte being PSA.

5. The method according to claim 1, said normalizing analyte being sodium.

6. The method according to claim 1, said normalizing analyte being chloride.

7. The method according to claim 1, said normalizing analyte being osmolality.

8. The method according to claim 1, further comprising measuring the level of a second normalizing analyte in said solution wherein the level of analyte in the blood from which said blood fluid specimen was collected is determined based on the level of said analyte and said second normalizing analyte in said solution.

9. The method according to claim 8, wherein a first blood analyte level is determined based on the levels in solution of said analyte and said normalizing analyte; a second blood analyte level is determined based on the levels in solution of said analyte and said second normalizing analyte; and the level of analyte in the blood from which said blood fluid specimen was collected is determined by calculating the mean average of said first and second blood analyte levels.

10. The method according to claim 9, wherein said first and second normalizing analytes are dissimilar and are each selected from the group consisting of sodium, chloride, and osmolality.

11. The method according to claim 1, comprising:  
receiving a first electrical signal corresponding to the level of analyte in said solution;  
receiving a second electrical signal corresponding to the level of normalizing analyte in said solution; and  
determining the level of analyte in the blood from which said blood fluid specimen was collected based on said first and second electrical signals.

12. The method according to claim 11, each of said first and second electrical signals being analog signals.

13. The method according to claim 1, comprising:  
determining the level of analyte in said solution; and  
calculating the level of analyte in the blood from which said blood fluid specimen was collected by multiplying said level of analyte in said solution by a correction factor, said correction factor being determined as a function of the level of normalizing analyte in said solution.

14. A method for determining the concentration of an analyte in blood from a solution formed from a dried blood fluid specimen, comprising:  
in either order, measuring the analyte level in said solution and measuring the level of a normalizing analyte; and  
determining the analyte level in the blood from which said blood fluid specimen was collected based on said analyte level in said solution and on said level of said normalizing analyte in said solution; said normalizing analyte being selected from the group consisting of sodium, chloride, and osmolality.

15. The method according to claim 14, said analyte being ALT.

16. The method according to claim 14, said analyte being a cholesterol.

17. The method according to claim 14, said analyte being PSA.

18. The method according to claim 16, said normalizing analyte being sodium.
19. The method according to claim 16, said normalizing analyte being chloride.
20. The method according to claim 16, said normalizing analyte being osmolality.
21. The method according to claim 14, further comprising measuring the level of a second normalizing analyte in said solution wherein the level of analyte in the blood from which said blood fluid specimen was collected is determined based on the level of said analyte and said second normalizing analyte in said solution.
22. The method according to claim 21, wherein a first blood analyte level is determined based on the levels in solutions of said analyte and said normalizing analyte; a second blood analyte level is determined based on the levels in solution of said analyte and said second normalizing analyte; and the level of analyte in the blood from which said blood fluid specimen was collected is determined by calculating the mean average of said first and second blood analyte levels.
23. The method according to claim 14, comprising:
  - receiving a first electrical signal corresponding to the level of analyte in said solution;
  - receiving a second electrical signal corresponding to the level of normalizing analyte in said solution; and
  - determining the level of analyte in the blood from which said blood fluid specimen was collected based on said first and second electrical signals.
24. The method according to claim 23, each of said first and second electrical signals being analog signals.
25. The method according to claim 14, comprising:
  - determining the level of analyte in said solution; and
  - calculating the level of analyte in the blood from which said blood fluid specimen was collected by multiplying said level of analyte in said solution by a correction factor, said correction factor being determined as a function of the level of normalizing analyte in said solution.



26. The method according to claim 14, said blood fluid specimen being a dried whole blood sample.

27. The method according to claim 14, said blood fluid specimen being a dried serum sample.

28. A method for determining the concentration of an analyte from a solution formed from a dried blood fluid specimen, comprising:

in any order, measuring the level of an analyte in said solution, measuring the level of a first normalizing analyte in said solution, and measuring the level of a second normalizing analyte in said solution;

determining the analyte level in the blood from which said blood fluid specimen was collected based on said analyte level in said solution, the level of said first normalizing analyte in said solution, and the level of said second normalizing analyte in said solution.

29. The method according to claim 28, said analyte being ALT.

30. The method according to claim 28, said analyte being a cholesterol.

31. A method according to claim 28, said analyte being PSA.

32. The method according to claim 28, further comprising measuring the level of a second normalizing analyte in said solution wherein the level of analyte in the blood from which said blood fluid specimen was collected is determined based on the level of said analyte and said second normalizing analyte in said solution.

33. The method according to claim 28, comprising:  
receiving a first electrical signal corresponding to the level of analyte in said solution;

receiving a second electrical signal corresponding to the level of the first normalizing analyte in said solution; and

determining the level of analyte in the blood from which said blood fluid specimen was collected based on said first and second electrical signals.

34. The method according to claim 33, each of said first and second electrical signals being analog signals.

35. The method according to claim 28, comprising:  
determining the level of analyte in said solution; and  
calculating the level of analyte in the blood from which said blood fluid specimen was collected by multiplying said level of analyte in said solution by a correction factor, said correction factor being determined as a function of the level of normalizing analyte in said solution.

36. A method for reporting a test result, comprising:  
receiving an incoming inquiry from a user;  
prompting said user for a test number;  
retrieving a test result from a database of test numbers and test results; and  
reporting said test results to said user, said test results comprising an analyte level having been determined according to claim 1.

37. A method for reporting a test result, comprising:  
receiving an incoming inquiry from a user;  
prompting said user for a test number;  
retrieving a test result from a database of test numbers and test results; and  
reporting said test results to said user, said test results comprising an analyte level having been determined according to claim 14.

38. A method for reporting a test result, comprising:  
receiving an incoming inquiry from a user;  
prompting said user for a test number;  
retrieving a test result from a database of test numbers and test results; and  
reporting said test results to said user, said test results comprising an analyte level having been determined according to claim 28.

39. A method for preparing a database of test results, comprising:  
receiving a test number;  
receiving a test result; and  
storing said test result and said test number in a database record, said test result comprising an analyte level having been determined according to claim 1.

40. A method for preparing a database of test results, comprising:  
receiving a test number;  
receiving a test result; and

storing said test result and said test number in a database record, said test result comprising an analyte level having been determined according to claim 14.

41. A method for preparing a database of test results, comprising:  
receiving a test number;  
receiving a test result; and  
storing said test result and said test number in a database record, said test result comprising an analyte level having been determined according to claim 28.

42. A method for preparing a database for use in determining an analyte level in blood based upon measurements of the analyte in a solution formed from a blood fluid specimen and based upon the measurement of first and second normalizing analytes in said solution, comprising:

providing a plurality of blood samples each having a known blood analyte level;  
for each of said blood samples, preparing a blood fluid specimen thereby yielding a plurality of blood fluid specimens;  
for each of said blood fluid specimens, forming a solution;  
for each of said solutions, measuring the levels of said analyte, a first normalizing analyte, and a second normalizing analyte in said solution; and  
recording in a database record the known blood analyte level, the level of analyte measured in said solution, the level of first normalizing analyte measured in said solution and the level of said second normalizing analyte measured in said solution.

43. The method according to claim 43, said analyte being ALT.

44. The method according to claim 43, said analyte being a cholesterol.

45. The method according to claim 43, said analyte being PSA.

46. The method according to claim 43, said first normalizing analyte being sodium.

47. The method according to claim 43, said first normalizing analyte being chloride.

48. The method according to claim 43, said first normalizing analyte being osmolality.

49. The method according to claim 43, said blood fluid specimen being a dried whole blood sample.

50. The method according to claim 43, said blood fluid specimen being a dried serum sample.

51. The method according to claim 43, wherein each of said plurality of blood fluid specimens is formed before the first of said database records is prepared.

52. The method according to claim 43, further comprising:  
after preparing a plurality of database records, deriving an algorithm from said database for calculating blood analyte levels from a solution analyte level, a first normalizing analyte level, and a second normalizing solution analyte level in a solution prepared from a blood fluid specimen.

53. The method according to claim 53, said algorithm being first order with respect to said solution analyte level.

54. The method according to claim 53, said algorithm being first order with respect to said solution analyte level, said first normalizing analyte level, and said second normalizing analyte level.

55. The method according to claim 43, said database comprising a computer file disposed in computer readable form on a computer readable medium.

56. A computer readable medium containing the computer file prepared in accordance with the method of claim 56.

57. A method for determining the concentration of an analyte in a body fluid specimen from a solution formed from an modified specimen, comprising:

in any order, measuring the level of an analyte in said solution, measuring the level of a first normalizing analyte in said solution, and measuring the level of a second normalizing analyte in said solution;

determining the analyte level in the specimen from which said modified specimen was collected based on said analyte level in said solution, the level of said first normalizing analyte in said solution, and the level of said second normalizing analyte in said solution.

58. A method according to claim 1, said blood fluid specimen comprising a dried whole blood specimen.

59. A method according to claim 28, said blood fluid specimen comprising a dried blood serum specimen.

60. A fluid collector comprising:  
an absorbent substrate coated with a saccharide polymer, said substrate permitting at least substantial separation of serum from red blood cells via differential wicking.

61. A fluid collector according to claim 60, said saccharide comprising xylose.

62. A kit comprising a device for obtaining blood in combination with the fluid collector of claim 60.

63. A fluid collection device comprising a superstrate and the fluid collector of claim 60, said fluid collector being generally fixed with respect to said superstrate, said fluid collector having an aperture defining a blood receiving opening and permitting access to said fluid collector.

64. A fluid collection device according to claim 63, said fluid collector having a first end and a second end, said aperture permitting access to said first end of said fluid collector, said superstrate having a second aperture relatively proximal said second end of said fluid collector.

65. A method for determining the level of an analyte in a fluid based on measurement of said analyte in a modified fluid specimen to be analyzed, comprising in any appropriate order:

providing a plurality of fluid specimens having a known measurable analyte level;

preparing a modified fluid specimen from each of said fluid specimens;

in either order, measuring the level of said analyte and at least one normalizing analyte in each of said modified fluid specimens thereby generating a data set;

using said data set, deriving an algorithm for determining the level of analyte as a function of analyte level measured in a modified specimen and normalizing analyte measured in a modified specimen;

determining the levels of said analyte and said normalizing analyte in said modified fluid specimen to be analyzed; and

calculating the level of said analyte in the fluid from which said modified specimen was obtained based on said algorithm.

66. A method according to claim 65, said fluid specimen comprising a blood fraction.

67. A method according to claim 66, said fluid specimen comprising blood serum.

68. A method according to claim 65, said modified fluid specimen comprising a dried blood serum specimen.

69. A method according to claim 65, said analyte being ALT.

70. A method according to claim 65, said being cholesterol.

71. A method according to claim 65, said being PSA.

72. A method according to claim 65, said normalizing analyte being sodium.

73. A method according to claim 65, said normalizing analyte being cholesterol.

74. A method according to claim 65, further comprising:  
measuring the level of a second normalizing analyte in said fluid specimens having a known or measurable analyte level, said algorithm being a function also of the second normalizing analyte level; and  
measuring the level of said second normalizing analyte in said modified fluid specimen to be analyzed.

FIG. 1




FIG. 2






FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10

Lab Reference Number

Home Access Health Corporation  
Hoffman Estates, IL 60195

919

Home Access Health Corporation  
Micro-Serum Collection Card

Name \_\_\_\_\_

Street \_\_\_\_\_

City \_\_\_\_\_

State \_\_\_\_ Zip \_\_\_\_\_

Ph \_\_\_\_\_

Date \_\_\_\_\_ Age \_\_\_\_\_

Dr. \_\_\_\_\_

918

906



(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
6 November 2003 (06.11.2003)

PCT

(10) International Publication Number  
**WO 2003/091736 A3**

(51) International Patent Classification<sup>7</sup>: **G01N 33/92**,  
33/574, B01L 3/00, G01N 33/48

(21) International Application Number:  
PCT/US2003/012674

(22) International Filing Date: 23 April 2003 (23.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/374,629 23 April 2002 (23.04.2002) US

(71) Applicant (*for all designated States except US*): **HOME  
ACCESS HEALTH CORPORATION** [US/US]; 2401  
West Hassell Road, Suite 1510, Hoffman Estates, IL 60195  
(US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **WANDELL,**  
**Michael** [US/US]; 7236 Holly Hall Drive, Mercer Island,  
WA 98040 (US). **VINOGRADOV, Ilia** [RU/US]; 170  
Hawthorne, Elmhurst, IL 60126 (US).

(74) Agents: **HOOVER, Allen, E.** et al.; Leydig, Voit & Mayer,  
Ltd., Two Prudential Plaza, Suite 4900, 180 North Stetson,  
Chicago, IL 60601-6780 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,  
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,  
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:  
16 September 2004

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: QUANTITATIVE ANALYSIS OF A BIOLOGICAL SAMPLE OF UNKNOWN QUANTITY

(57) Abstract: Disclosed is a method for testing a modified specimen such as a dried blood spot, plasma or serum specimen, for an analyte of interest, such as cholesterol. In accordance with the disclosed subject matter, the level of the analyte of interest in the medium from which the modified specimen was obtained (e.g., from a patient's blood) is determined based on the level of an analyte in a solution formed from the modified specimen and on the level of at least one normalizing analyte. The analyte and normalizing analyte each may be an ion, compound, biochemical entity, or property of the specimen. Also disclosed are a fluid collector and a fluid collection device.



WO 2003/091736 A3

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G01N33/92 G01N33/574 B01L3/00 G01N33/48

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	-/-	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken as the state of the art
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

22 October 2003

Date of mailing of the international search report

25-05-2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2640, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-2018

Authorized officer

Thumb, W

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 03/12674

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ERHARDT JUERGEN G ET AL: "Rapid and simple measurement of retinol in human dried whole blood spots" JOURNAL OF NUTRITION, vol. 132, no. 2, February 2002 (2002-02), pages 318-321, XP002258787 ISSN: 0022-3166 abstract	1,5,13, 14,18, 25,26, 39,40, 58,65, 68,72
Y		2-4, 6-12, 15-17, 19-24, 27-38, 41-55, 57,59, 66,67, 69-71, 73,74
X	page 319, column 1, paragraph 6 - column 2, paragraph 1  ERHARDT JUERGEN G ET AL: "Combined measurement of retinol and soluble transferrin receptor (sTfR) in a single dried blood spot (DBS) stored at room temperature" FASEB JOURNAL, vol. 16, no. 4, 20 March 2002 (2002-03-20), pages A247-A248, XP009019440 Annual Meeting of the Professional Research Scientists on Experimental Biology; New Orleans, Louisiana, USA; April 20-24, 2002 ISSN: 0892-6638 the whole document	1,5,13 14,18, 25,26, 39,40, 58,65, 68,72
Y		2-4, 6-12, 15-17, 19-24, 27-38, 41-55, 57,59, 66,67, 69-71, 73,74
X	US 6 187 531 B1 (TYRRELL STEVEN P) 13 February 2001 (2001-02-13)  the whole document	1,3,4, 13,14, 16,17, 25,26, 58,65, 68,70,71

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	EP 0 419 196 A (NOVA BIOMEDICAL CORP) 27 March 1991 (1991-03-27) the whole document	65-67
Y	WO 00/44930 A (ABBOTT LAB) 3 August 2000 (2000-08-03)  page 4, line 25 - page 7, line 26	1, 2, 11, 12, 14, 15, 23, 24, 28, 29, 33, 34, 42, 43, 65, 69
Y	US 5 935 775 A (SAVJANI GOPAL V) 10 August 1999 (1999-08-10)  the whole document	1, 4, 14, 17, 28, 31, 42, 45, 65, 71
Y	EP 0 503 356 B (FRESENIUS AG) 30 October 1996 (1996-10-30) the whole document	7, 20, 48
A	O'BRIEN J M ET AL: "Detection of hepatitis C antibody with at-home collection kits using an innovative laboratory algorithm" INFECTIOUS DISEASES IN CLINICAL PRACTICE 2001 UNITED STATES, vol. 10, no. 9, 2001, pages 474-480, XP001155589 ISSN: 1056-9103 the whole document	1-59, 65-74
A	US 6 226 378 B1 (QUATTROCCHI RICHARD A) 1 May 2001 (2001-05-01) cited in the application the whole document	1-59, 65-74

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 03/12671

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 36-38  
because they relate to subject matter not required to be searched by this Authority, namely:  
Rule 39.1(v) PCT - Presentation of information
2. ☒ Claims Nos.: 56  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6 4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-59, 65-74

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Claims Nos.: 36-38

Rule 39.1(v) PCT - Presentation of information

-----

Continuation of Box I.2

Claims Nos.: 56

Claim 56 refers to itself. It is thus not clear which program codes are actually found on the computer readable medium. Should claim 56 refer to a computer readable medium comprising a database of analyte levels, said claim would not be allowed under the provisions of Rule 39.1(v).

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/12674

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6187531	B1	13-02-2001	US 6040135 A	21-03-2000
			US 6524533 B1	25-02-2003
EP 0419196	A	27-03-1991	US 5001067 A	19-03-1991
			AT 123338 T	15-06-1995
			CA 2025327 A1	19-03-1991
			DE 69019794 D1	06-07-1995
			DE 69019794 T2	21-12-1995
			EP 0419196 A2	27-03-1991
			IE 903362 A1	10-04-1991
			JP 3170057 A	23-07-1991
			PT 95332 A	22-05-1991
			US 5118473 A	02-06-1992
WO 0044930	A	03-08-2000	US 6565738 B1	20-05-2003
			CA 2359321 A1	03-08-2000
			EP 1147215 A1	24-10-2001
			JP 2002535666 T	22-10-2002
			WO 0044930 A1	03-08-2000
US 5935775	A	10-08-1999	AU 2431897 A	22-10-1997
			WO 9737035 A1	09-10-1997
EP 0503356	B	16-09-1992	DE 4107689 A1	10-09-1992
			DE 59207443 D1	05-12-1996
			EP 0503356 A2	16-09-1992
			ES 2093124 T3	16-12-1996
US 6226378	B1	01-05-2001	US 5978466 A	02-11-1999
			US 6014438 A	11-01-2000
			US 2002137025 A1	26-09-2002
			US 2001012611 A1	09-08-2001
			US 6016345 A	18-01-2000
			AU 8131894 A	19-06-1995
			WO 9515493 A1	08-06-1995